Cyclerion Therapeutics Inc expected to post a loss of 30  cents a share - Earnings Preview

Korsana Biosciences

21/02/2022 19:34

* Cyclerion Therapeutics Inc  CYCN.OQ   CYCN.O  is expected
to report results on February 23 (estimated).
    * The Boston Massachusetts-based  company is expected to
report
revenue of $900 thousand, according to the mean estimate from 2
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Cyclerion
Therapeutics
Inc is for a loss of 30 cents per share. For the same quarter
last year, the company reported a loss of 54 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cyclerion
Therapeutics Inc is $9​, about 88.7% above​ its last closing
price of $1.02. ​​​

This summary was machine generated February 21 at 19:34 GMT. 
All figures in US dollars  unless otherwise stated